sur Theranexus (EPA:ALTHX)
THX Pharma successfully completes its €7.8 million capital increase
THX Pharma, specializing in rare neurological diseases, has announced a €7.8 million fundraising round. The operation, aimed at supporting the company's development and financial structure, was a success thanks to shareholder engagement. The issuance of 4,356,804 shares at a price of €1.80 per share saw a subscription rate of 44.3%. In parallel, subscription commitments secured the financing through guarantees provided by various investors.
The funds will support the company's key projects, including the development of TX01 and Batten-1. TX01 is slated for commercialization in 2027, while Batten-1 is expected to reach the market in 2028. In addition, the company is developing an antisense oligonucleotide platform for other rare diseases.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Theranexus